8-K filing — ANAVEX LIFE SCIENCES CORP. (AVXL)
Filed: 2026-09-09 AccNo: 0001731122-26-001211 Size: 184 KB Item 8.01: Other Events
Stocks · News reference
Reported Earlier, PVG Urges Anavex Stockholders To Vote GOLD Proxy Card For Six Nominees After ISS Cites Board Oversight Lapses
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
Anavex Life Sciences Corp. (AVXL) announced it has regained compliance with Nasdaq listing rules after filing outstanding Form 10-Qs for Q2 and Q3 2026. The company will host a conference call on September 9, 2026, where Interim CEO Terrie Kellmeyer will discuss clinical development strategy and priorities, with focus on Alzheimer's Disease programs.
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company
PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.